Skip to main content

Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer (EMEA/CHMP/BWP/271475/2006)

 The guideline with the reference number "EMEA/CHMP/BWP/271475/2006" pertains to "Potency Testing of Cell-Based Immunotherapy Medicinal Products for the Treatment of Cancer." This guideline was developed by the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP) and is specific to cell-based immunotherapy products intended for cancer treatment. Here is an overview of this guideline:


1. Purpose and Scope:

The primary purpose of this guideline is to provide recommendations and regulatory guidance for the potency testing of cell-based immunotherapy medicinal products used in the treatment of cancer. Potency testing is essential to ensure the effectiveness and consistency of these products.

2. Applicability:

The guideline applies to cell-based immunotherapy products, such as cancer vaccines and adoptive cell therapies, which harness the patient's immune system to target and destroy cancer cells.

3. Definitions:

The document provides definitions of key terms and concepts relevant to the potency testing of cell-based immunotherapy products.

4. General Principles:

The guideline outlines general principles for the design and conduct of potency assays specific to the product's mechanism of action. These principles ensure that the assays accurately assess the product's intended therapeutic effect.

5. Target Antigens and Mechanisms:

It discusses the importance of selecting relevant target antigens and mechanisms of action for potency testing based on the specific cell-based immunotherapy product.

6. Assay Development:

Recommendations are provided for the development of potency assays, including considerations for assay sensitivity, specificity, precision, and robustness.

7. In Vitro Assays:

The guideline emphasizes the use of in vitro assays that simulate the interaction between the cell-based immunotherapy product and its target, providing relevant information on the product's potency.

8. In Vivo Assays:

In some cases, in vivo assays may be necessary to assess the product's potency, particularly when in vitro assays cannot adequately replicate the product's mechanism of action.

9. Validation and Qualification:

The guideline discusses the validation and qualification of potency assays to ensure their reliability and consistency.

10. Documentation and Reporting:

- It provides recommendations on the documentation and reporting of potency testing results in regulatory submissions.

11. Specificity and Sensitivity:

- The guideline addresses the importance of specificity and sensitivity in potency assays to ensure that they accurately measure the intended therapeutic effect and do not yield false-positive or false-negative results.

12. Stability Testing:

- Recommendations are provided for conducting stability testing to assess the potency of cell-based immunotherapy products over their shelf life.

13. Bridging Studies:

- If changes are made to the manufacturing process or product formulation, the guideline discusses the need for bridging studies to demonstrate that the potency assay remains relevant and consistent.


This guideline is essential for ensuring that cell-based immunotherapy products for cancer treatment are effectively and consistently evaluated for potency, contributing to their safety and efficacy. It provides a framework for manufacturers to develop and validate appropriate potency assays and communicate this information to regulatory authorities. Please note that the specific requirements and recommendations may evolve, so it's important to consult the most up-to-date version of the guideline on the EMA's official website or through regulatory authorities

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more